96-hour infusion of paclitaxel in advanced bronchioloalveolar carcinoma
Rachel Murphy
This article has no abstract so we have provided the first paragraph of the full text.
Bronchioloalveolar carcinoma (BAC) is a histologic subgroup of non-small-cell lung cancer (NSCLC) that accounts for 2–5% of new NSCLC cases. The relative infrequency of BAC has meant that few clinical trials for this disease have been performed. Focal BAC can be cured by resection, but no optimal therapy for multilobar or recurrent disease has been established. Paclitaxel is one of the most commonly used agents for the treatment of NSCLC, and prolonged infusion of paclitaxel has demonstrated significant activity in in vitro studies, clinical studies in NSCLC, and in anecdotal cases of BAC.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.